Article

Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.

Department of Nuclear Medicine, Korea Cancer Center Hospital, Seoul, Korea.
Journal of Nuclear Medicine (Impact Factor: 5.56). 08/2009; 50(9):1435-40. DOI: 10.2967/jnumed.109.063602
Source: PubMed

ABSTRACT Response to neoadjuvant chemotherapy is a significant prognostic factor for osteosarcoma; however, this information can be determined only after surgical resection. If we could predict histologic response before surgery, it might be helpful for the planning of surgeries and tailoring of treatment. We evaluated the usefulness of (18)F-FDG PET for this purpose.
A total of 70 consecutive patients with a high-grade osteosarcoma treated at our institute were prospectively enrolled. All patients underwent (18)F-FDG PET and MRI before and after neoadjuvant chemotherapy. We analyzed the predictive values of 5 parameters, namely, maximum standardized uptake values (SUVs), before and after (SUV2) chemotherapy, SUV change ratio, tumor volume change ratio, and metabolic volume change ratio (MVCR) in terms of their abilities to discriminate responders from nonresponders.
Patients with an SUV2 of less than or equal to 2 showed a good histologic response, and patients with an SUV2 of greater than 5 showed a poor histologic response. The histologic response of a patient with an intermediate SUV2 (2 < SUV2 </= 5) was found to be predictable using MVCR. A patient with an MVCR of less than 0.65 is likely to be a good responder, whereas a patient with an MVCR of greater than or equal to 0.65 is likely to be a poor responder. According to our model, the predictive values for good responders and poor responders were 97% (31/32) and 95% (36/38), respectively.
We found that combined information on (18)F-FDG PET and MRI scans, acquired before and after chemotherapy, could be used to predict histologic response to neoadjuvant chemotherapy in osteosarcoma.

Download full-text

Full-text

Available from: Gi Jeong Cheon, May 04, 2014
0 Followers
 · 
111 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, the automatic segmentation of Osteosar-coma in MRI images is formed as a clustering problem. Subsequently, a new dynamic clustering algorithm based on the Harmony Search (HS) hybridized with Fuzzy C-means (FCM) called DCHS is proposed to automatically segment the Osteosarcoma MRI images in an intelligent manner. The concept of variable length in each harmony memory vector is applied to encode variable numbers of candidate cluster centers at each iteration. Furthermore, a new HS operator, called the 'empty operator' is introduced to support the selection of empty decision variables in the harmony memory vector. FCM is incorporated in DCHS to fine tune the segmentation results. Our approach uses multi-spectral information from STIR (Short Tau Inversion Recovery) and T2-weighted MRI sequences. We used a subset of Haralick texture features and pixel intensity values as a feature space to DCHS to delineate the tumour volume. The segmentation results were statistically evaluated against manually delineated data for four patients. Promising results were obtained with average of 0.72 of Dice measurement. In addition, we also propose a method to identify necrotic tissue within the tumour in order to monitor drug-induced necrosis of tumor tissue.
    Soft Computing and Pattern Recognition (SoCPaR), 2010 International Conference of; 01/2010
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article briefly reviews malignant bone tumors, diffuse marrow infiltrating diseases, and other benign bone diseases with fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT) that should be differentiated from malignant tumors. Clinical use of FDG PET/CT in (1) primary malignant bone tumors including osteosarcoma, malignant fibrous histiocytoma, and primary bone lymphoma, (2) hematopoietic tumors with bone marrow involvement, such as plasmacytoma, multiple myeloma, lymphoma and leukemia, and (3) benign tumors and tumor-like lesions including hemangioma, neurogenic tumor, fibrous dysplasia, and nodular fasciitis are presented, with an emphasis on various imaging findings on FDG PET/CT. Benign tumors and tumor-like conditions are often incidentally detected on FDG PET/CT in serial follow-up studies of cancer patients and should be differentiated from metastasis.
    Seminars in Musculoskeletal Radiology 04/2014; 18(2):133-48. DOI:10.1055/s-0034-1371016 · 0.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This research aims to investigate the potential of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET) to predict pathologic response after neoadjuvant chemotherapy (NAC) and overall survival (OS) of patients with synovial sarcoma in Korea. Twenty patients with synovial sarcoma from January 2001 to December 2011 were reviewed retrospectively. All patients underwent pre-treatment FDG PET and tumor removal. Patients were classified with the maximum SUV (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), age, sex, histologic subtype, tumor size, NAC, resection margin, and metastasis at diagnosis. Pathologic response was assessed using the French Federation of Cancer Centers system. Statistical analyses were analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards regression model, and Mann-Whitney test. Nine patients (45 %) showed pathologic response, and ten patients survived. Higher SUVmax, higher MTV, higher TLG, monophasic epithelial type, and metastasis at diagnosis were significantly related to poorer OS (p = 0.047, 0.016, 0.016, 0.045, and 0.018, respectively). By multivariate analysis, metastasis at diagnosis was significantly related to poorer OS (p = 0.012/HR = 5.9, 95 % CI 1.47 to 24.1). The SUVmax, MTV, and TLG of the non-responder group were significantly higher than those of the responder group (p = 0.020, 0.020, and 0.020, respectively). There was no significant difference in size between the two groups (p = 0.062). A higher SUVmax on the pre-treatment scan, monophasic epithelial type, and metastasis at diagnosis were significantly associated with a poorer OS, and pathologic responders showed a higher SUVmax before NAC. The PET parameters can be used to predict OS and pathologic response in patients with synovial sarcomas before NAC.
    03/2015; 49(1):33-41. DOI:10.1007/s13139-014-0301-5